Floatz logo

Dostarlimab

Endometrial Carcinosarcoma

ARCAGY/ GINECO GROUPmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Endometrial Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
GOG Foundation
Phase 3B
Carboplatin
GOG Foundation
Phase 3B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Niraparib
ARCAGY/ GINECO GROUP
Phase 2/3B
Trabectedin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2B

View all 14 →

Same molecule, other indications

Dostarlimab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Neoplasms, ColonDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →